SCHEMBL5402349

SCHEMBL5402349

CN(C)CCN(Cc1ccccc1)C(=O)c1ccccc1-c1ccccc1C(=O)N(CCC(=O)O)Cc1cccnc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 2/20 0.50
KMT2A Q03164 2/20 0.49
ROCK1 Q13464 1/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 3/20 0.46
MAPT P10636 1/20 0.46
PKM P14618 1/20 0.44
LIMK2 P53671 1/20 0.43
TBXAS1 P24557 3/20 0.43
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
PDK1 Q15118 1/20 0.43
CHRNB2 P17787 1/20 0.43
CHRNA4 P43681 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5409445 0.94 CHRNA7 (0.46) KCNA5KMT2AROCK1MEN1ALDH1A1
SCHEMBL5392909 0.93 TSHR (0.51) KCNA5KMT2AALDH1A1MAPTPKM
SCHEMBL5409427 0.92 ALDH1A1 (0.53) KCNA5KMT2AMEN1ALDH1A1MAPT
SCHEMBL5397896 0.90 KMT2A (0.52) KMT2AMEN1ALDH1A1LIMK2
SCHEMBL5395565 0.89 KMT2A (0.51) KCNA5KMT2AALDH1A1MAPTPKM
SCHEMBL5400712 0.88 LTB4R2 (0.51) KCNA5KMT2AALDH1A1MAPTLIMK2
SCHEMBL5403047 0.87 KCNA5 (0.46) KCNA5KMT2AALDH1A1MAPTPKM
SCHEMBL5418597 0.86 TRPV1 (0.47) KCNA5KMT2AMEN1ALDH1A1MAPT
SCHEMBL5409277 0.85 TSHR (0.48) KCNA5KMT2AALDH1A1MAPTTBXAS1
SCHEMBL5398588 0.85 KMT2A (0.45) KMT2AROCK1MEN1ALDH1A1LIMK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB KCNA5 3586/4885KMT2A 2451/4885ROCK1 4043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.